Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,081,975
-$1,674,736 QoQ
Shares Held
83,146
-62.2% QoQ
Ownership
0.114%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Squarepoint Ops LLC holds $1,094,861,392 across 233 Biotechnology names. ZYME ranks #72 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
426,723 | $141,189,839 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
162,814 | $125,796,608 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,349,516 | $64,736,282 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
695,276 | $52,208,274 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
556,324 | $41,312,620 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
52,884 | $27,683,187 | |
| 7 | ARQT |
Arcutis Biotherapeutics, Inc.
|
1,103,490 | $25,998,224 | |
| 8 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,705,829 | $24,666,287 |
All Filings in ZYME
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,081,975 | 83,146 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $3,756,711 | 219,948 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,952,767 | 155,599 | Shares | Defined | 2025-08-27 | |
| 2025-03-31 | $757,499 | 63,602 | Shares | Defined | 2025-08-27 | |
| 2024-09-30 | $419,646 | 33,438 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $623,987 | 73,324 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $153,676 | 14,608 | Shares | Defined | 2024-05-15 | |
| 2023-03-31 | $709,676 | 78,504 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||